During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, Should the telomerase inhibitor imetelstat become SoC in transfusion-dependent low-risk MDS?
In this video, Platzbecker reports the promising data, presented at ASH 2020, on the telomerase inhibitor imetelstat.